|
Administration of aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas. |
| |
|
Stock and Other Ownership Interests - pdox |
| |
|
Honoraria - Bayer; Eisai; PharmaMar |
Speakers' Bureau - PharmaMar |
Research Funding - CytRx Corporation (Inst) |
| |
|
Employment - Counterpoint Medical; Prana Biotechnology; Uptick Health |
Leadership - Counterpoint Medical; Prana Biotechnology; Uptick Health |
Stock and Other Ownership Interests - Counterpoint Medical; Prana Biotechnology; Uptick Health |
Honoraria - Amgen; Bristol-Myers Squibb; CytRx Corporation; Eisai; Immune Design; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals |
Consulting or Advisory Role - Amgen; CytRx Corporation; Eisai; Immune Design; Morphotek; PharmaMar; Threshold Pharmaceuticals |
Speakers' Bureau - HERON; Janssen Oncology |
Research Funding - Amgen (Inst); CytRx Corporation (Inst); Esanex (Inst); Immune Design (Inst); Johnson & Johnson (Inst); Morphotek (Inst); PharmaMar (Inst); TRACON Pharma (Inst) |
Expert Testimony - Novartis |
| |
|
Research Funding - CytRx Corporation (Inst) |
| |
|
Stock and Other Ownership Interests - Counterpoint Biomedica |
Research Funding - CytRx Corporation (Inst) |
Patents, Royalties, Other Intellectual Property - Counterpoint Biomedica |
| |
|
Research Funding - CytRx Corporation (Inst) |
| |
|
Research Funding - CytRx Corporation (Inst) |
| |
|
Employment - CytRx Corporation |
Stock and Other Ownership Interests - CytRx Corporation |
Research Funding - CytRx Corporation |
| |
|
Employment - CytRx Corporation |
| |
|
Employment - CytRx Corporation |
Stock and Other Ownership Interests - CytRx Corporation |
| |
|
No Relationships to Disclose |